SFM
DNA.WS

Soros Fund Management’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Soros Fund Management’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80,000
Closed -$58K – 243
2022
Q3 		$58K Hold
80,000
– – ﹤0.01% 204
2022
Q2 		$42K Buy
+80,000
New +$50.7K ﹤0.01% 210

Other funds holding DNA.WS

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
JRCM
Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return

Soros Fund Management's DNA.WS Position: Q4 2022 in Review

Soros Fund Management sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q4 2022, closing a stake of 80,000 shares — an estimated $58K sold.

Soros Fund Management first reported a position in DNA.WS in Q2 2022 and held it in 2 quarters. The position peaked at $58K in Q3 2022. 44 funds tracked by Wall St. Rank hold DNA.WS as of Q4 2022.

  • Soros Fund Management reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q4 2022 after selling out during the quarter.
  • Soros Fund Management sold 80,000 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q4 2022, an estimated $58K.
  • Soros Fund Management first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q2 2022 and held it in 2 quarters.
  • Soros Fund Management's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $58K in Q3 2022.
  • 44 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q4 2022.

Based on Soros Fund Management's 13F filing for Q4 2022, filed 13 Feb 2023.